NewsBenzingaDaré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance Benzinga 2026.10.02 20:05 (GMT+0) Open on Benzinga Other news Novo Provides Update On The Denecimig Biologics License Application In The US; The FDA Has Informed Novo That The BLA Review Of Denecimig For The Treatment Of Haemophilia A Is Still Ongoing; The FDA Has Not Communicated A New Timeline For Regulatory... Sean Parker is rebuilding Stability AI around music Applied Digital’s Revenue Is Likely About to Plunge. Don’t Let That Fool You on October 7. GameStop CEO Ryan Cohen Reports Open Market Purchase Of 700,000 Co's Class A Shares On Oct 2 At $24.4061/Share 12 Information Technology Stocks Moving In Friday's After-Market Session 12 Industrials Stocks Moving In Friday's After-Market Session
Novo Provides Update On The Denecimig Biologics License Application In The US; The FDA Has Informed Novo That The BLA Review Of Denecimig For The Treatment Of Haemophilia A Is Still Ongoing; The FDA Has Not Communicated A New Timeline For Regulatory...
GameStop CEO Ryan Cohen Reports Open Market Purchase Of 700,000 Co's Class A Shares On Oct 2 At $24.4061/Share
